EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Fundación Jiménez Díaz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (8)
2020
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517
2019
-
Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease
Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508
2018
-
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092
-
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents
Clinical Genitourinary Cancer, Vol. 16, Núm. 4, pp. e777-e784
2017
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572